Vincel Cordry
Psychiatry · Oklahoma City, OKNPI 1750359311
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Johnson & Johnson at 32.5% of the total. Reporting peaked in 2021 at $637 and has fallen 72.7% since, to $174 in 2025.
Across 163 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$774
- AbbVie$412
- Lundbeck LLC$240
- Teva Pharmaceuticals USA, Inc.$180
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$176
- Alkermes, Inc.$162
- plus $439 from 9 others
What the payments were for
- Food & beverage$2,36399%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 62 | $774 |
| AbbVie(2 entities) | 32 | $412 |
| Lundbeck LLC | 12 | $240 |
| Teva Pharmaceuticals USA, Inc. | 17 | $180 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $176 |
| Alkermes, Inc. | 8 | $162 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| Indivior Inc. | 4 | $67 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Supernus Pharmaceuticals, Inc. | 2 | $52 |
| Neurocrine Biosciences, Inc. | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $35 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Neuronetics, Inc. | 1 | $16 |
How this compares
$2,382 in reported general payments places this provider in the 80th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $11,678 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $7,818 |
| Lisdexamfetamine Dimesylate | 32 | $6,724 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 97 | $5,710 |
| Clozapine | 37 | $2,024 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 23 | $1,620 |
| Hydroxyzine Pamoate | 29 | $1,489 |
| Atomoxetine Hcl | 16 | $1,409 |
| Quetiapine Fumarate | 35 | $579 |
| Prazosin Hcl | 25 | $543 |
| Oxcarbazepine | 18 | $479 |
| Bupropion XlBupropion Hcl | 14 | $449 |
| Clonazepam | 32 | $368 |
| Bupropion Hcl SrBupropion Hcl | 17 | $332 |
| Propranolol Hcl | 23 | $270 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Oklahoma City
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Josephine DeguzmanOklahoma City$38K
- Haisam Al KhouriOklahoma City$10K
- Patrick HornOklahoma City$8K
- Shreekuma VinekarOklahoma City$7K
- Relindis TitaOklahoma City$6K
- Janita ArdisOklahoma City$6K
- Fiona LiOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.